Astellas Pharma is an API and finished-dose manufacturer based in Japan. It holds one valid CEP across a filed portfolio of 2 molecules. Its filings concentrate with MHRA (UK), DKMA (DK) and SWISSMEDIC (CH).
| Site | FDA FEI |
|---|---|
| Wallisellen, Switzerland | Not on file |
| Tokyo, Japan | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Tacrolimus | SFDA (Saudi Arabia) | 1 |
| Tamsulosin | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MHRA (UK) | 61 | None |
| DKMA (DK) | 35 | None |
| SWISSMEDIC (CH) | 31 | None |
| ANSM (FR) | 14 | None |
| SFDA (Saudi Arabia) | 13 | None |
| FAMHP (BE) | 11 | None |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Ask Fred what the record holds on Astellas Pharma, including filings and inspection history.
Chat with Fred, your AI analystRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.